Search research articles
Contact Us
Filters
Showing results (101-110 of 109) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 109 results.
Oncogene
|
July 4, 2012
Targeting Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor cells in vitro and in vivo
R B Luwor, B Baradaran, L E Taylor, et al.
Brain : a Journal of Neurology
|
July 30, 2004
MRI-negative PET-positive temporal lobe epilepsy: a distinct surgically remediable syndrome
R P Carne, T J O'Brien, C J Kilpatrick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 17, 1998
Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer
K Clarke, R L Basser, D Maher, et al.
Neurobiology of Disease
|
January 12, 2011
Stargazin and AMPA receptor membrane expression is increased in the somatosensory cortex of Genetic Absence Epilepsy Rats from Strasbourg
J T T Kennard, R Barmanray, S Sampurno, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1997
Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease
D J Morgan, J S Hill, K Clarke, et al.
Cancer Chemotherapy and Pharmacology
|
April 2, 1998
Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease
D J Morgan, J S Hill, K Clarke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2001
Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrin
M A Rosenthal, B Kavar, J S Hill, et al.
British Journal of Cancer
|
July 3, 2008
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs
D M Ashley, C D Riffkin, M M Lovric, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma
K Clarke, R L Basser, C Underhill, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 109) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 109 results.
Oncogene
|
July 4, 2012
Targeting Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor cells in vitro and in vivo
R B Luwor, B Baradaran, L E Taylor, et al.
Brain : a Journal of Neurology
|
July 30, 2004
MRI-negative PET-positive temporal lobe epilepsy: a distinct surgically remediable syndrome
R P Carne, T J O'Brien, C J Kilpatrick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 17, 1998
Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer
K Clarke, R L Basser, D Maher, et al.
Neurobiology of Disease
|
January 12, 2011
Stargazin and AMPA receptor membrane expression is increased in the somatosensory cortex of Genetic Absence Epilepsy Rats from Strasbourg
J T T Kennard, R Barmanray, S Sampurno, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1997
Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease
D J Morgan, J S Hill, K Clarke, et al.
Cancer Chemotherapy and Pharmacology
|
April 2, 1998
Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease
D J Morgan, J S Hill, K Clarke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2001
Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrin
M A Rosenthal, B Kavar, J S Hill, et al.
British Journal of Cancer
|
July 3, 2008
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs
D M Ashley, C D Riffkin, M M Lovric, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma
K Clarke, R L Basser, C Underhill, et al.
Page
of 11